Stromal cell-derived factor 1α mediates resistance to mTOR-directed therapy in pancreatic cancer

Neoplasia (United States)

Volumn 14, Issue 8, 2012, Pages 690-701

  Weekes, Colin D ^a   Song, Dongweon ^b   Arcaroli, John ^a   Wilson, Lora A ^a   Rubio Viqueira, Belen ^b,c   Cusatis, George ^b   Garrett Mayer, Elizabeth ^d   Messersmith, Wells A ^a   Winn, Robert A ^a,e   Hidalgo, Manuel ^b,c  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c Centro Nacional de Investigations Oncológicas   (Spain)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR7; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; MAMMALIAN TARGET OF RAPAMYCIN; MYC PROTEIN; N [1, 4, 8, 11 TETRAAZACYCLOTETRADECANYL 1, 4 PHENYLENEBIS (METHYLENE) ] 2 (AMINOMETHYL) PYRIDINE; PROTEIN C FOS; PROTEIN KINASE B; PROTEIN S6; SERINE; STROMAL CELL DERIVED FACTOR 1ALPHA; TEMSIROLIMUS; THREONINE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CONTROLLED STUDY; EXPLANT; FEMALE; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PANCREAS CANCER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84865223823     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.111810     Document Type: Article

References (48)

1. Yeo CJ, Cameron JL, Lillemoe KD, Sohn TA, Campbell KA, Sauter PK, Abrams RA, and Hruban RH (2002). Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for peri-ampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity and mortality. Ann Surg 236, 355-368.
2. Hruban RH, Adsay NV, Albores-Saavedra J, Compton C, Garrett ES, Goodman SN, Kern SE, Klimstra DS, Klöppel G, Longnecker DS, et al. (2001). Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic ductal lesions. Am J Surg Pathol 25, 579-586.
3. Wilentz RE, Iacobuzio-Donahue CA, Argani P, McCarthy DM, Parsons JL, Yeo CJ, Kern SE, and Hruban RH (2000). Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res 60, 2002-2006.
4. Hingorani SR, Petricoin EF III, Maitra A, Rajapakse V, King C, Jacobetz MA, Ross S, Conrads TP, Veenstra TD, Hitt BA, et al. (2003). Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4, 437-450.
5. Agbunag C and Bar-Sagi D (2004). Oncogenic K-ras drives cell cycle progression and phenotypic conversion of primary pancreatic duct epithelial cells. Cancer Res 64, 5650-5663.
6. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, and Perucho M (1988). Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53, 549-554.
7. s6k signaling is required for pancreatic cancer cell proliferation. J Surg Res 97, 123-130.
8. s6k pathway in human pancreatic cancer cells. Cancer Res 59, 3581-3587.
9. Sengupta S, Peterson TR, and Sabatini DM (2010). Regulation of the mTOR complex 1 pathway by nutrients, growth factors and stress. Mol Cell 40, 310-322.
10. CIP1 cooperate in enforcing rapamycin-induced G1 arrest and determine the cellular response to rapamycin. Cancer Res 61, 3373-3381.
11. Cip1. Mol Cell 11, 1491-1501.
12. Ito S, Fujimoto K, Mori T, Kami K, Kolzumi M, Toyoda E, Kawaguchi Y, and Doi R (2006). In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer. Int J Cancer 118, 2237-2243.
13. Wolpin BM, Hezel AF, Abrams T, Blazkowsky LS, Meyerhardt JA, Chan JA, Enzinger PC, Allen B, Clark JW, Ryan DP, et al. (2009). Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol 27, 193-198.
14. Javle MM, Shroff RT, Xiong H, Varadhachary GA, Fogelman D, Reddy SA, Davis D, Zhang Y, Wolff RA, and Abbruzzese JL (2010). Inhibition of the mammalian target of rapamycin [mTOR] in advanced pancreatic cancer: results of two phase II studies. BMC Cancer 10, 368-374.
15. Garrido-Laguna I, Tan AC, Usom M, Angenendt M, Ma WW, Villaroel MC, Zhao M, Rajeshkumar NV, Jimeno A, Donehower R, et al. (2010). Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer. Br J Cancer 103, 649-655.
16. Zou YR, Kottmann AH, Kuroda M, Taniuchi I, and Littman DR (1998). Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 393, 524-525.
17. Balabanian K, Lagane B, Infantino S, Chow KY, Harriague J, Moepps B, Arenzana-Seisdedos F, Thelen M, and Bachelerie F (2005). The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J Biol Chem 280, 35760-35766.
18. Muller A, Homey B, and Soto H (2001). Involvement of chemokine receptors in breast cancer metastasis. Nature 410, 50-56.
19. Guleng B, Tateishi K, Ohta M, Kanai F, Jazag A, Ijichi H, Tanaka Y, Washida M, Morikane K, Fukushima Y, et al. (2005). Blockade of the stromal cell- derived factor-1/CXCR4 axis attenuates in vivo tumor growth by inhibiting angiogenesis in a vascular endothelial growth factor-independent manner. Cancer Res 65, 5864-5871.
20. Barbero S, Bonavia R, Bajetto A, Porcile C, Pirani P, Ravetti JL, Zona GL, Spaziante R, Florio T, and Schettini G (2003). Stromal cell-derived factor 1α stimulates human glioblastoma cell growth through the activation of both extracellular signal-regulated kinase 1/2 and Akt. Cancer Res 63, 1969-1974.
21. Philips R, Burdick M, Lutz M, Belperio JA, Keane MP, and Strieter RM (2003). The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am J Crit Care Med 167, 1676-1686.
22. Kayali AG, Van Gunst K, Campbell IL, Stotland A, Kritzik M, Liu G, Flodström-Tullberg M, Zhang YQ, and Sarvetnick N (2003). The stromal derived factor-1α/CXCR4 ligand-receptor axis is critical for progenitor survival and migration in the pancreas. J Cell Biol 163, 859-869.
23. Shen X, Artinyan A, Jackson D, Thomas RM, Lowy AM, and Kim J (2010). Chemokine receptor CXCR4 enhances proliferation in pancreatic cancer cells through AKT and ERK dependent pathways. Pancreas 39, 81-87.
24. Liang JJ, Zhu S, Bruggeman R, Zaino RJ, Evans DB, Fleming JB, Gomez HF, Zander DS, and Wang H (2010). High levels of expression of human stromal cell- derived factor-1 are associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma. Cancer Epidemiol Biomarkers Prev 10, 2598-2604.
25. Thomas RM, Kim J, Revelo-Penaflel MP, Angel R, Dawson DW, and Lowy AM (2008). The chemokine receptor CXCR4 is expressed in pancreatic intra-epithelial neoplasia. Gut 57, 1555-1560.
26. Wehler T, Wolfert F, Schimanski CC, Gockel I, Herr W, Biesterfeld S, Seifert JK, Adwan H, Berger MR, Junginger T, et al. (2006). Strong expression of chemokine receptor CXCR4 by pancreatic cancer correlates with advanced disease. Oncol Rep 16, 1159-1164.
27. Rubio-Viqueira B, Jimeno A, Cusatis G, Zhang X, Iacobuzio-Donahue C, Karikari C, Shi C, Danenberg K, Danenberg PV, Kuramochi H, et al. (2006). An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res 12, 4652-4661.
28. Gebauer F, Tachezy M, Effenberger K, von Loga K, Zander H, Marx A, Kaifi JT, Sauter G, Izbicki JR, and Bockhorn M (2011). Prognostic impact of CXCR4 and CXCR7 expression in pancreatic adenocarcinoma. J Surg Oncol 104, 140-145.
29. Gera JF, Mellinghoff IK, Shi Y, Rettig MB, Tran C, Hsu J, Sawyers CL, and Lichtenstein AK (2004). AKT activity determines sensitivity to mammalian target of rapamycin [mTOR] inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem 279, 2737-2746.
30. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, et al. (2007). Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25, 1960-1966.
31. Jimeno A, Kulesza P, Bouaroud N, Chan A, Forastiere A, Brahmer J, Clark DP, and Hidalgo M (2006). C-fos assessment as a marker of anti-epidermal growth factor receptor effect. Cancer Res 66, 2385-2390.
32. de Nigris F, Crudele V, Giovane A, Casamassimi A, Giordano A, Garban HJ, Cacciatore F, Pentimalli F, Marquez-Garban DC, Petrillo A, et al. (2010). CXCR4/YY1 inhibition impairs VEGF network and angiogenesis during malignancy. Proc Natl Acad Sci USA 107, 14484-14489.
33. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, et al. (1997). Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15, 2403-2413.
34. Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bejetta E, Schuller J, Saletti P, Bauer J, Figer A, Pestalozzi B, et al. (2007). Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 25, 2212-2217.
35. Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, Harper PG, Dunn J, Tudur-Smith C, West J, et al. (2009). Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 27, 5513-5518.
36. Jones S, Zhang X, Parsons DW, Lin JC-H, Leary RJ, Agenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, et al. (2008). Core signaling pathways inhuman pancreatic cancers revealed by global genomic analyses. Science 321, 1801-1806.
37. Porcile C, Bajetto A, Barbieri F, Barbero S, Bonavia R, Biglieri M, Pirani P, Florio T, and Schettini G (2005). Stromal cell-derived factor-1α [SDF-1α/ CXCL12] stimulates ovarian cancer cell growth through the EGF receptor transactivation. Exp Cell Res 308, 241-253.
38. Phillips RJ, Mestas J, Gharaee-Kermani M, Burdick MD, Sica A, Belperio JA, Keane MP, and Strieter RM (2005). Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1alpha. J Biol Chem 280, 22473-22481.
39. Chakravarti A, Loeffler JS, and Dyson NJ (2002). Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phospho-inositide 3-kinase signaling. Cancer Res 62, 200-207.
40. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, et al. (2007). MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039-1043.
41. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, et al. (2009). Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324, 1457-1461.
42. Philip PA, Benedetti J, Corless CL, Wong R, O'Reilly EM, Flynn PJ, Rowland KM, Atkins JN, Mirtsching BC, Rivkin SE, et al. (2010). Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 28, 3605-3610.
43. Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O'Reilly E, Wozniak TF, et al. (2010). Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B [CALGB 80303]. J Clin Oncol 28, 3617-3622.
44. Mueller MT, Hermann PC, Witthauer J, Rubio-Viqueira B, Leicht SF, Huber S, Ellwart JW, Mustafa M, Bartenstein P, D'Haese JG, et al. (2009). Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer. Gastroenterology 137, 1102-1113.
45. Grunewald M, Avraham I, Dor Y, Bachar-Lustig E, Itin A, Jung S, Chimenti S, Landsman L, Abramovitch R, and Keshet E (2006). VEGF-induced adult neo-vascularization: recruitment, retention and role of accessory cells. Cell 124, 175-189.
46. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL, and Weinberg RA (2005). Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121, 335-348.
47. Matsusue R, Kubo H, Hisamori S, Okoshi K, Takagi H, Hida K, Nakano K, Itami A, Kawada K, Nagayama S, et al. (2009). Hepatic stellate cells promote liver metastasis of colon cancer cells by the action of SDF-1/CXCR4 axis. Ann Surg Oncol 16, 2645-2653.
48. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ, and Heeschen C (2007). Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1, 313-323.